Muscle, bone and GLP-1: the resistance-training conversation.

1. The data: lean mass loss is real

When weight is lost, fat mass is the priority of the conversation. But weight is not just fat. Every kilogram lost on any caloric deficit, including a GLP-1-induced one, is a mix of fat mass, lean mass (muscle, organs, connective tissue) and water. The proportion is not fixed.

Across the GLP-1 trial literature, body composition substudies show that approximately 25 to 40% of weight lost on semaglutide or tirzepatide is lean mass. The DEXA substudy of STEP-1 (n=140), reported in the Wilding 2021 NEJM publication (Supplementary Appendix Table S5) and detailed in the ENDO 2021 substudy abstract by Wilding and colleagues, showed that participants on semaglutide 2.4 mg lost on average about 15% of body weight (around 14.8 kg from a 98.4 kg baseline), of which approximately 8 kg was fat mass and approximately 5 kg was lean mass.¹ In SURMOUNT-1, Jastreboff and colleagues reported substantial losses in both fat and lean compartments with tirzepatide, with a higher proportion of fat mass loss but a non-trivial lean mass component (around 25% of total weight loss in the dedicated body-composition substudy).²

This proportion is not unique to GLP-1 therapy; any caloric deficit produces lean mass loss, and the proportion in GLP-1 trials is broadly comparable to non-pharmacological caloric restriction in adults living with obesity. What is specific is the speed: GLP-1 therapy can produce in 6 to 12 months a magnitude of weight loss that lifestyle programmes typically reach over years. The lean mass conversation is therefore proportionally more important on AOM than on a slow lifestyle trajectory.

2. Why lean mass matters

Three reasons why lean mass is not "a number on a body composition scan", but a clinical signal worth protecting:

• Basal metabolic rate. Muscle tissue is metabolically active. Losing it lowers daily energy expenditure, which makes long-term weight maintenance harder.
• Functional capacity. Muscle is what lets you climb stairs, lift a grandchild, recover from illness or surgery. Less of it means more fragility.
• Future regain trajectory. After eventual treatment discontinuation or treatment intensity reduction (see our article on stopping GLP-1), the body composition you are left with shapes the regain pattern. A higher fat-to-lean ratio increases the metabolic and functional cost of regain.

A specific risk in older adults and people with low baseline muscle mass is sarcopenic obesity: the combination of excess adiposity and low muscle, associated with worse functional outcomes, more falls, and higher mortality. The international literature consistently flags this as a population in whom the muscle-preservation question is urgent, not optional.

3. The bone density question

The bone density signal during GLP-1 therapy is less consistent than the muscle signal. Some short-term studies report mild reductions in bone mineral density during weight loss on GLP-1; others do not. The interpretation is complicated, because rapid weight loss in general (regardless of whether it is pharmacological, surgical or behavioural) is a known risk factor for bone loss in some populations.

What clinicians watch:

• Post-menopausal women, who are already at higher fracture risk.
• Older adults with prior fractures or an osteoporosis history.
• Adults with very rapid weight loss trajectories (above the trial average) and concurrent low calcium and vitamin D intake.

The bone density question is not a reason to avoid an effective medical treatment. It is a reason to discuss with your physician whether you are in a higher-stakes group, and what monitoring (if any) is warranted. For most adults, the practical answer is also the muscle answer: load the skeleton with resistance training, support intake with adequate protein and micronutrients.

4. What resistance training does during caloric deficit

Resistance training (the deliberate loading of muscle against an external resistance) is the single most effective behavioural intervention for preserving lean mass during a caloric deficit. The literature on this is mature.

The narrative review by Cava, Yeat and Mittendorfer in Advances in Nutrition (2017), titled "Preserving Healthy Muscle during Weight Loss", synthesised the evidence: resistance training combined with adequate protein intake during energy restriction substantially attenuates lean mass loss compared with caloric restriction alone, in healthy adults and in older adults.⁴

The mechanism is well understood. Resistance loading stimulates muscle protein synthesis. In the absence of that signal, the body, faced with energy deficit, breaks down muscle as part of the energy economy. With the signal, the same body preferentially mobilises fat. The intervention does not require heroic volumes; it requires consistency.

5. Protein: how much, when, what

Adequate protein intake is the second leg of muscle preservation. The general adult recommendation (the WHO/FAO 0.8 g/kg/day) was set decades ago for nitrogen balance in non-deficit conditions. It is now widely considered too low for adults in caloric deficit, and certainly too low for older adults.

Recent evidence-based recommendations:

• During an active weight-loss phase, 1.2 to 1.6 g/kg of body weight per day, ideally calibrated on adjusted body weight rather than total body weight in adults with high body mass.⁴
• Distributed across the day, with 25 to 40 g of high-quality protein per main meal, rather than concentrated in one meal.
• Combined with resistance training within the same day, ideally within a few hours of the session, although the precise window is less critical than total daily intake.

For older adults specifically, the PROT-AGE international position paper recommends 1.0 to 1.2 g/kg/day in healthy older adults, and 1.2 to 1.5 g/kg/day in those with acute or chronic disease, with similar distribution principles.³

In practical terms on a GLP-1, where appetite is reduced and meals are smaller, this means: protein at every meal, every day, prioritised before other macronutrients. We unpack this in eating on GLP-1 without counting calories.

6. Building a sustainable plan: the "non-gym person" version

Resistance training does not require a gym membership, an athletic background, or a complex programme. It requires three principles:

• Compound movements. Squats, hinges (deadlift pattern), pushes, pulls, carries. These movements load multiple muscle groups, and they have the highest signal-to-noise ratio of any exercise selection.
• Progressive overload. Slowly increasing the load, the volume, or the difficulty over time. Progress does not need to be linear; it needs to exist.
• Frequency. Two to three sessions per week is supported by the literature for general muscle preservation in adults during caloric deficit. More is not better at this stage; consistency is.

The American College of Sports Medicine position stand on resistance training summarises the evidence-based dosing for novice adults: 8 to 12 repetitions per set at a moderate-to-vigorous load, two to three times per week (Ratamess et al., 2009).⁵ The ACSM/AHA recommendations for healthy adults add coverage of 8 to 10 exercises across major muscle groups (Garber et al., 2011).⁶

Practical entry points that work for people who do not consider themselves "gym people":

• Bodyweight progressions at home (squat to chair, push-up against a wall progressing to floor, deadlift pattern with a heavy bag).
• Resistance bands, which are cheap, portable and surprisingly effective.
• A short, supervised series of sessions with a qualified physiotherapist or exercise professional, especially if you have joint issues or a long sedentary period behind you.

The point is not to become an athlete. It is to send the muscle-protection signal regularly enough that the body keeps the muscle, while the GLP-1 does its job on appetite.

7. Older adults, post-menopausal women: the higher-stakes case

The principles above apply to all adults on GLP-1 therapy. They apply with particular urgency to:

• Adults aged 65 and over, in whom baseline muscle mass is already declining, and in whom sarcopenic obesity is a recognised clinical entity.
• Post-menopausal women, in whom bone density and lean mass loss can compound.
• Adults with a history of fractures, falls, or low baseline physical activity.

For these groups, a structured conversation with the physician about resistance training, protein intake, vitamin D status and (where appropriate) a baseline DEXA, is part of the AOM care plan, not an optional add-on. International obesity-care frameworks position physical activity and body composition support as part of obesity care, not as separate lifestyle advice. We give a short side-effects timeline that complements this in GLP-1 side effects, month by month.

8. The takeaway

GLP-1 therapy is highly effective at producing weight loss. It is also a treatment that produces a real, measurable lean mass loss, in a proportion that matters clinically and functionally. The evidence-based response is not to avoid the treatment; it is to scaffold it.

Two questions, asked at every consultation, would change the body composition trajectory of most adults on AOM:

• Are you doing two to three sessions of resistance training per week, in some form?
• Are you reaching 1.2 to 1.6 g/kg/day of protein, distributed across meals?

If the answer is no, the response is not guilt; it is a small adjustment, sustained over months. If the answer is yes, the rest of the AOM trajectory looks different. The conversation is not optional; it is part of the medical care.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
3. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association 2013;14(8):542-559. doi:10.1016/j.jamda.2013.05.021. PMID 23867520.
4. Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Advances in Nutrition 2017;8(3):511-519. doi:10.3945/an.116.014506. PMID 28507015.
5. Ratamess NA, Alvar BA, Evetoch TK, et al. (American College of Sports Medicine). Position Stand: Progression Models in Resistance Training for Healthy Adults. Medicine & Science in Sports & Exercise 2009;41(3):687-708. doi:10.1249/MSS.0b013e3181915670. PMID 19204579.
6. Garber CE, Blissmer B, Deschenes MR, et al. (American College of Sports Medicine). Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise. Medicine & Science in Sports & Exercise 2011;43(7):1334-1359. doi:10.1249/MSS.0b013e318213fefb. PMID 21694556.